Bottom line
FBDIX vs RYOIX: the short answer
FBDIX (Franklin Biotechnology Discovery Fund) and RYOIX (Biotechnology Fund) share a meaningful slice of their top holdings — about 45% by weight.
FBDIX is cheaper at 1.01% vs 1.38% — a difference of $37 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs +4.0% for RYOIX.
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
FBDIX vs RYOIX side by side
| FBDIX | RYOIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Franklin Templeton | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 1.01% | 1.38% |
| Annual cost per $10k | $101 | $138 |
| 10-yr cost on $10k (prospectus) | $1,728 | $1,709 |
| Max front load | 5.5% | — |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +43.9% | +30.7% |
| 5-yr return (annualized) | +5.0% | +4.0% |
| 10-yr return (annualized) | +6.4% | +5.9% |
| Best quarter | +29.5% | +28.3% |
| Worst quarter | −24.5% | −22.5% |
| Net assets (fund) | $1.2B | $136.8M |
| Number of holdings | 126 | 74 |
| Portfolio turnover | 38% | 75% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBDIX | RYOIX | Difference |
|---|---|---|---|
| 2025 | +52.3% | +30.7% | +21.6% |
| 2024 | +4.0% | −0.7% | +4.7% |
| 2023 | +18.4% | +6.1% | +12.3% |
| 2022 | −12.7% | −13.1% | +0.4% |
| 2021 | −17.7% | +1.8% | −19.5% |
| 2020 | +29.9% | +22.1% | +7.8% |
| 2019 | +34.8% | +25.0% | +9.8% |
| 2018 | −15.7% | −9.0% | −6.7% |
| 2017 | +18.8% | +29.7% | −10.9% |
| 2016 | −17.2% | −19.5% | +2.3% |
Source: Fund prospectus bar charts
Holdings overlap
12 of FBDIX's top 25 holdings also appear in RYOIX's top 25.
| Holding | FBDIX | RYOIX |
|---|---|---|
| Jazz Pharmaceuticals plc | 5.66% | 1.42% |
| Amgen, Inc. | 4.39% | 5.05% |
| Gilead Sciences, Inc. | 3.86% | 4.49% |
| Regeneron Pharmaceuticals, Inc. | 3.77% | 2.93% |
| Argenx SE | 3.62% | 1.48% |
| Vertex Pharmaceuticals, Inc. | 3.54% | 4.32% |
| Revolution Medicines, Inc. | 3.01% | 2.48% |
| Guardant Health, Inc. | 2.76% | 1.72% |
| Insmed, Inc. | 1.99% | 1.79% |
| Neurocrine Biosciences, Inc. | 1.82% | 1.52% |
| Bridgebio Pharma, Inc. | 1.67% | 1.38% |
| Cytokinetics, Inc. | 1.24% | 1.35% |
Source: SEC Form N-PORT
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between FBDIX and RYOIX?
Which is cheaper, FBDIX or RYOIX?
Should I own both FBDIX and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.